DT-101

DRUG3 trials

Sponsors

Draig Therapeutics Limited, Draig Therapeutics Ltd

Conditions

Major Depressive DisorderMajor Depressive Disorder (MDD)

Phase 2

A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression

RecruitingNCT07300969

Draig Therapeutics LtdMajor Depressive Disorder (MDD)

Start: 2025-12-16End: 2027-08-01Target: 300Updated: 2026-08-26

A Phase 2 Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of DT-101 in Adults with Major Depressive Disorder

Not yet recruitingCTIS2025-522784-15-00

Draig Therapeutics LimitedMajor Depressive Disorder

Target: 38Updated: 2026-02-24

A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression

RecruitingNCT07610473

Draig Therapeutics LtdMajor Depressive Disorder (MDD)

Start: 2026-05-14End: 2027-05-01Target: 118Updated: 2026-09-02